Early Wearing-Off Effect of OnabotulinumtoxinA in Chronic Migraine: A Prospective Real-Life Study
Abstract
1. Background
2. Material and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Lipton, R.B.; Silberstein, S.D. Episodic and chronic migraine headache: Breaking down barriers to optimal treatment and prevention. Headache 2015, 55 (Suppl. 2), 103–126. [Google Scholar] [CrossRef]
- Tonini, M.C.; Fiorencis, A.; Iannacchero, R.; Zampolini, M.; Cappuccio, A.; Raddino, R.; Grillo, E.; Albanese, M.; Allais, G.; Bassano, M.A.; et al. Narrative Medicine to integrate patients’, caregivers’ and clinicians’ migraine experiences: The DRONE multicentre project. Neurol. Sci. 2021, 42, 5277–5288. [Google Scholar] [CrossRef] [PubMed]
- Steiner, T.J.; Stovner, L.J.; Jensen, R.; Uluduz, D.; Katsarava, Z. Lifting The Burden: The Global Campaign against Headache. Migraine remains second among the world’s causes of disability, and first among young women: Findings from GBD2019. J. Headache Pain 2020, 21, 137. [Google Scholar] [CrossRef] [PubMed]
- GBD (2019) Diseases and injuries collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the global burden of disease study 2019. Lancet 2020, 396, 1204–1222. [Google Scholar] [CrossRef] [PubMed]
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013, 33, 629–808. [Google Scholar] [CrossRef]
- Quintas, S.; García-Azorín, D.; Heredia, P.; Talavera, B.; Gago-Veiga, A.B.; Guerrero, Á.L. Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients. Pain Med. 2019, 20, 1815–1821. [Google Scholar] [CrossRef]
- Munakata, J.; Hazard, E.; Serrano, D.; Klingman, D.; Rupnow, M.F.; Tierce, J.; Reed, M.; Lipton, R.B. Economic burden of transformed migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009, 49, 498–508. [Google Scholar] [CrossRef]
- Sacco, S.; Lampl, C.; Maassen van den Brink, A.; Caponnetto, V.; Braschinsky, M.; Ducros, A.; Little, P.; Pozo-Rosich, P.; Reuter, U.; Ruiz de la Torre, E.; et al. Burden and attitude to resistant and refractory migraine: A survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J. Headache Pain 2021, 22, 39. [Google Scholar]
- Buse, D.C.; Silberstein, S.D.; Manack, A.N.; Papapetropoulos, S.; Lipton, R.B. Psychiatric comorbidities of episodic and chronic migraine. J. Neurol. 2013, 260, 1960–1969. [Google Scholar] [CrossRef]
- Dresler, T.; Caratozzolo, S.; Guldolf, K.; Huhn, J.I.; Loiacono, C.; Niiberg-Pikksööt, T.; Puma, M.; Sforza, G.; Tobia, A.; Ornello, R.; et al. Understanding the nature of psychiatric comorbidity in migraine: A systematic review focused on interactions and treatment implications. J. Headache Pain 2019, 20, 51. [Google Scholar] [CrossRef]
- Negro, A.; Curto, M.; Lionetto, L.; Martelletti, P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: A real-world experience. J. Headache Pain 2015, 17, 1. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, T.T.; Ornello, R.; Quatrosi, G.; Torrente, A.; Albanese, M.; Vigneri, S.; Guglielmetti, M.; Maria De Marco, C.; Dutordoir, C.; Colangeli, E.; et al. Medication overuse and drug addiction: A narrative review from addiction perspective. J. Headache Pain 2021, 22, 32. [Google Scholar] [CrossRef] [PubMed]
- Albanese, M. Clinical Management of Migraine. J. Clin. Med. 2022, 11, 5225. [Google Scholar] [CrossRef] [PubMed]
- Masters-Israilov, A.; Robbins, M.S. OnabotulinumtoxinA Wear-off Phenomenon in the Treatment of Chronic Migraine. Headache 2019, 59, 1753–1761. [Google Scholar] [CrossRef] [PubMed]
- Aurora, S.K.; Dodick, D.W.; Turkel, C.C.; DeGryse, R.E.; Silberstein, S.D.; Lipton, R.B.; Diener, H.C.; Brin, M.F.; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010, 30, 793–803. [Google Scholar] [CrossRef] [PubMed]
- Diener, H.C.; Dodick, D.W.; Aurora, S.K.; Turkel, C.C.; DeGryse, R.E.; Lipton, R.B.; Silberstein, S.D.; Brin, M.F.; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010, 30, 804–814. [Google Scholar] [CrossRef]
- Dodick, D.W.; Turkel, C.C.; DeGryse, R.E.; Aurora, S.K.; Silberstein, S.D.; Lipton, R.B.; Diener, H.C.; Brin, M.F.; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010, 50, 921–936. [Google Scholar] [CrossRef]
- Guerzoni, S.; Pellesi, L.; Baraldi, C.; Pini, L.A. Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. J. Headache Pain 2015, 17, 48. [Google Scholar] [CrossRef][Green Version]
- Khan, F.A.; Mohammed, A.E.; Poongkunran, M.; Chimakurthy, A.; Pepper, M. Wearing Off Effect of OnabotulinumtoxinA Near the End of Treatment Cycle for Chronic Migraine: A 4-Year Clinical Experience. Headache 2020, 60, 430–440. [Google Scholar] [CrossRef]
- Gago-Veiga, A.B.; Santos-Lasaosa, S.; Cuadrado, M.L.; Guerrero, Á.L.; Irimia, P.; Láinez, J.M.; Leira, R.; Pascual, J.; Sanchez Del Río, M.; Viguera, J.; et al. Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice. Neurol. (Engl. Ed.) 2019, 34, 408–417. [Google Scholar] [CrossRef]
- Blumenfeld, A.M.; Aurora, S.K.; Laranjo, K.; Papapetropoulos, S. Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurol. 2015, 15, 100. [Google Scholar] [CrossRef] [PubMed]
- Cernuda-Morollón, E.; Ramón, C.; Larrosa, D.; Alvarez, R.; Riesco, N.; Pascual, J. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? Cephalalgia 2015, 35, 864–868. [Google Scholar] [CrossRef] [PubMed]
- Aicua-Rapun, I.; Martínez-Velasco, E.; Rojo, A.; Hernando, A.; Ruiz, M.; Carreres, A.; Porqueres, E.; Herrero, S.; Iglesias, F.; Guerrero, A.L. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year. J. Headache Pain 2016, 17, 112. [Google Scholar] [CrossRef] [PubMed]
- Domínguez, C.; Pozo-Rosich, P.; Torres-Ferrús, M.; Hernández-Beltrán, N.; Jurado-Cobo, C.; González-Oria, C.; Santos, S.; Monzón, M.J.; Latorre, G.; Álvaro, L.C.; et al. OnabotulinumtoxinA in chronic migraine: Predictors of response. A prospective multicentre descriptive study. Eur. J. Neurol. 2018, 25, 411–416. [Google Scholar] [CrossRef]
- Ruscheweyh, R.; Athwal, B.; Gryglas-Dworak, A.; Frattale, I.; Latysheva, N.; Ornello, R.; Pozo-Rosich, P.; Sacco, S.; Torres Ferrus, M.; Stark, C.D. Wear-Off of OnabotulinumtoxinA Effect over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries. Headache 2020, 60, 1673–1682. [Google Scholar] [CrossRef]
- Kollewe, K.; Escher, C.M.; Wulff, D.U.; Fathi, D.; Paracka, L.; Mohammadi, B.; Karst, M.; Dressler, D. Long-term treatment of chronic migraine with OnabotulinumtoxinA: Efficacy, quality of life and tolerability in a real-life setting. J. Neural Transm. (Vienna) 2016, 123, 533–540. [Google Scholar] [CrossRef]
- Santos Lasaosa, S.; Pozo Rosich, P. (Eds.) Manual de Práctica Clínica en Cefaleas. Recomendaciones Diagnóstico-Terapéuticas de la Sociedad Española de Neurología 2020; Luzán 5: Madrid, Spain, 2020. [Google Scholar]
- Zigmond, A.S.; Snaith, R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67, 361–370. [Google Scholar] [CrossRef]
- Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J. Clin. Epidemiol. 2008, 61, 344–349. [Google Scholar] [CrossRef]
- Aoki, K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26, 785–793. [Google Scholar] [CrossRef]
- Peres, M.F.P.; Mercante, J.P.P.; Tobo, P.R.; Kamei, H.; Bigal, M.E. Anxiety and depression symptoms and migraine: A symptom-based approach research. J. Headache Pain 2017, 18, 37. [Google Scholar] [CrossRef]
- Winner, P.K.; Blumenfeld, A.M.; Eross, E.J.; Orejudos, A.C.; Mirjah, D.L.; Adams, A.M.; Brin, M.F. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study. Drug Saf. 2019, 42, 1013–1024. [Google Scholar] [CrossRef] [PubMed]
Baseline | Visit 2 (after 1st Cycle) | Visit 3 (tras 2nd Cycle) | |
---|---|---|---|
Female sex n (%) | 55 (93.2) | ||
Age mean (SD) | 44 (12) | ||
Years of CM mean (SD) | 5.09 (4.4) | ||
Migraine with aura n (%) | 8 (13.6) | ||
Obesity n (%) | 7 (11.9) | ||
Sleep disorders n (%) | 14 (23.7) | ||
Depression n (%) | 21 (35.6) | ||
Anxiety n (%) | 21 (35.6) | ||
Depression and anxiety disorder n (%) | 26 (44.1) | ||
Arterial hypertension n (%) | 4 (6.8) | ||
Fybromyalgia n (%) | 4 (6.8) | ||
Medication overuse n (%) | 37 (64.9) | 27 (45.8) | 25 (42.4) |
Previous OPT mean (SD) | 3.21 (1.28) | ||
Topiramate n (%) | 37 (62.7) | ||
Beta-blockers n (%) | 32 (54.2) | ||
Flunarizine n (%) | 43 (72.9) | ||
Anti Hypertensive n (%) | 2 (3.4) | ||
Amitriptyline n (%) | 50 (84.7) | ||
Others n (%) | 12 (20.3) | ||
Migraine days mean (SD) | 16.34 (8.26) | 10.92 (6.95) | 11.19 (7.34) |
Headache days mean (SD) | 23.07 (7.38) | 15.81 (9.53) | 15.24 (9.46) |
Triptan intake days mean (SD) | 8.96 (9.66) | 5.91 (6.1) | 5.95 (6.23) |
Analgesic intake days mean (SD) | 15.71 (12.06) | 10.93 (10.74) | 10.49 (10.68) |
Intensity of headache mean (SD) | 8.24 (1.8) | 7.3 (1.56) | 7.28 (1.50) |
HIT-6 mean (SD) | 67.11 (6.97) | 63.85 (6.07) | 63.49 (7.34) |
MIDAS mean (SD) | 71.39 (65.73) | 44 (39.96) | 46.02 (43.99) |
Conversion to EM n (%) | 18 (30.5) | 16 (27.1) |
WOE in 24 Patients (40.6%) | ||||
---|---|---|---|---|
Cycle 1 | Cycle 2 | |||
WOE 8-Week | WOE 10-Week | WOE 8-Week | WOE 10-Week | |
Patients | 7 (11.9%) | 14 (23.7%) | 7 (11.9%) | 7 (11.9%) |
Total | 21 (35.6%) | 14 (23.8%) |
Without WOE (n = 35) | With WOE (n = 24) | p Value | |
---|---|---|---|
Female sex n (%) | 31 (88.6) | 24 (100) | 0.115 |
Age mean (SD) | 45.57 (11.6) | 41.88 (12.55) | 0.25 |
Years of CM mean (SD) | 5.75 (5.25) | 4 (2.22) | 0.162 |
Migraine with aura n (%) | 6 (17.14) | 2 (16.67) | 0.33 |
Depression n (%) | 10 (28.57) | 11 (45.83) | 0.174 |
Anxiety n (%) | 9 (25.71) | 12 (50) | 0.05 |
Depression and anxiety disorder n (%) | 11 (31.4) | 15 (62.5) | 0.018 |
Medication overuse n (%) | 24 (68.57) | 13 (54.17) | 0.327 |
Previous OPT mean (SD) | 3.23 (1.42) | 3.17 (1.07) | 0.875 |
Migraine days mean (SD) | 14.94 (7.68) | 18.33 (8.8) | 0.125 |
Headache days mean (SD) | 23.29 (7.37) | 22.75 (7.54) | 0.787 |
Triptan intake days mean (SD) | 8.91 (9.07) | 9.05 (10.84) | 0.96 |
Analgesic intake days mean (SD) | 15.35 | 16.39 (13.2) | 0.77 |
Intensity of headache mean (SD) | 8.09 (2.1) | 8.5 (1.15) | 0.422 |
HIT-6 mean (SD) | 67.1 (7.49) | 67.14 (6.39) | 0.98 |
MIDAS mean (SD) | 83.18 (72.64) | 52.86 (49.17) | 0.09 |
155 U OnabotA 1st cycle n (%) | 3 (8.57) | 6 (25) | 0.18 |
WOE in 1 Cycle (n = 13) | WOE in 2 Cycles (n = 11) | p Value | |
---|---|---|---|
Years of CM mean (SD) | 4.91 (2.46) | 2.62 (0.51) | 0.009 |
Migraine days mean (SD) | 20.85 (9.44) | 15.36 (7.29) | 0.131 |
Headache days mean (SD) | 24.23 (7.94) | 21 (6.97) | 0.306 |
Triptan intake days mean (SD) | 11.18 (12.63) | 6.44 (8.11) | 0.345 |
Analgesic intake days mean (SD) | 18.3 (12.72) | 14 (14.26) | 0.5 |
Intensity of headache mean (SD) | 8.5 (1.38) | 8.7 (0.75) | 1 |
HIT-6 mean (SD) | 67.75 (7.31) | 66.4 (8.11) | 0.634 |
MIDAS mean (SD) | 80.82 (53.65) | 22.1 (12.95) | 0.005 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rodríguez-Montolio, J.; Navarro-Pérez, M.P.; Almeida-Zurita, M.; Santos-Lasaosa, S. Early Wearing-Off Effect of OnabotulinumtoxinA in Chronic Migraine: A Prospective Real-Life Study. J. Clin. Med. 2023, 12, 5360. https://doi.org/10.3390/jcm12165360
Rodríguez-Montolio J, Navarro-Pérez MP, Almeida-Zurita M, Santos-Lasaosa S. Early Wearing-Off Effect of OnabotulinumtoxinA in Chronic Migraine: A Prospective Real-Life Study. Journal of Clinical Medicine. 2023; 12(16):5360. https://doi.org/10.3390/jcm12165360
Chicago/Turabian StyleRodríguez-Montolio, Joana, María Pilar Navarro-Pérez, Monserrath Almeida-Zurita, and Sonia Santos-Lasaosa. 2023. "Early Wearing-Off Effect of OnabotulinumtoxinA in Chronic Migraine: A Prospective Real-Life Study" Journal of Clinical Medicine 12, no. 16: 5360. https://doi.org/10.3390/jcm12165360
APA StyleRodríguez-Montolio, J., Navarro-Pérez, M. P., Almeida-Zurita, M., & Santos-Lasaosa, S. (2023). Early Wearing-Off Effect of OnabotulinumtoxinA in Chronic Migraine: A Prospective Real-Life Study. Journal of Clinical Medicine, 12(16), 5360. https://doi.org/10.3390/jcm12165360